garadacimab

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Drugs.com
Wed, 03/1/23 - 10:07 am
CSL
clinical trials
garadacimab
HAE
CSL reports Phase III data for garadacimab to treat hereditary angioedema
Clinical Trials Arena
Thu, 08/18/22 - 12:30 pm
CSL
clinical trials
garadacimab
HAE
hereditary angiodema